Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor

SA Hjorth, K Thirstrup and TW Schwartz

Laboratory for Molecular Pharmacology 6321, Rigshospitalet, Copenhagen, Denmark. siv@molpharm.dk

A series of kappa/mu receptor chimeras and a number of kappa receptors substituted in the second transmembrane segment (TM-II) were investigated using as radioligands, respectively, the kappa-selective agonist [3H]C1977 and the nonselective opioid antagonist [3H]diprenorphine (DIP). All of the receptor constructs bound [3H]DIP with similar and high affinity, whereas the apparent affinity of the nonpeptide agonist C1977, when estimated in competition binding with the antagonist [3H]DIP, was impaired between 42- and > 500-fold in the kappa/mu chimeras and between 64- and 153-fold in three of the kappa receptor mutants that had been substituted in the TM-II segment. However, homologous competition binding experiments, using [3H]C1977 as radioligand, showed that the high affinity binding of this nonpeptide agonist was in fact not impaired in four of the kappa/mu chimeras and in three TM-II substituted kappa receptors compared with the wild-type kappa receptor. In all cases in which mutations decreased the apparent affinity of C1977 without affecting its actual affinity, as determined in homologous assays using [3H]C1977, the calculated number of receptor sites (Bmax) was decreased. In three of the kappa/mu constructs, binding of [3H]C1977 was undetectable, indicating that in these chimeras the affinity of the nonpeptide agonist had actually been affected. Also, for the kappa-selective peptide agonist dynorphin A(1- 8), the measured affinity for the receptor mutants was strongly dependent on whether it was determined using the antagonist [3H]DIP or the agonist [3H]C1977 in that < or = 800-fold higher Ki values were determined in competition with the antagonist. It is concluded that mutations in the kappa-opioid receptor can cause large discrepancies between the affinity determined for agonists in homologous versus heterologous competition binding assays and that this pattern, which is compatible with a partial uncoupling of receptors, is observed in surprisingly many types of receptor mutations.

Volume 50, Issue 4, pp. 977-984, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. M. Rosenkilde, R. David, I. Oerlecke, T. Benned-Jensen, U. Geumann, A. G. Beck-Sickinger, and T. W. Schwartz Conformational Constraining of Inactive and Active States of a Seven Transmembrane Receptor by Metal Ion Site Engineering in the Extracellular End of Transmembrane Segment V Mol. Pharmacol., December 1, 2006; 70(6): 1892 - 1901. [Abstract] [Full Text] [PDF]

				D. Ott, R. Frischknecht, and A. Pluckthun Construction and characterization of a kappa opioid receptor devoid of all free cysteines Protein Eng. Des. Sel., January 1, 2004; 17(1): 37 - 48. [Abstract] [Full Text] [PDF]

				G. Pineyro, M. Azzi, A. De Lean, P. Schiller, and M. Bouvier Short-Term Inverse-Agonist Treatment Induces Reciprocal Changes in delta -Opioid Agonist and Inverse-Agonist Binding Capacity Mol. Pharmacol., October 1, 2001; 60(4): 816 - 827. [Abstract] [Full Text] [PDF]

				Y. Lin, X. Jian, Z. Lin, G. S. Kroog, S. Mantey, R. T. Jensen, J. Battey, and J. Northup Two Amino Acids in the Sixth Transmembrane Segment of the Mouse Gastrin-Releasing Peptide Receptor Are Important for Receptor Activation J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1053 - 1062. [Abstract] [Full Text]

				M. M. Rosenkilde and T. W. Schwartz Potency of Ligands Correlates with Affinity Measured against Agonist and Inverse Agonists but Not against Neutral Ligand in Constitutively Active Chemokine Receptor Mol. Pharmacol., March 1, 2000; 57(3): 602 - 609. [Abstract] [Full Text]

				U. Gether Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors Endocr. Rev., February 1, 2000; 21(1): 90 - 113. [Abstract] [Full Text]

				M. M. Rosenkilde, T. N. Kledal, H. Brauner-Osborne, and T. W. Schwartz Agonists and Inverse Agonists for the Herpesvirus 8-encoded Constitutively Active Seven-transmembrane Oncogene Product, ORF-74 J. Biol. Chem., January 8, 1999; 274(2): 956 - 961. [Abstract] [Full Text] [PDF]

				D. Massotte, L. Baroche, F. Simonin, L. Yu, B. Kieffer, and F. Pattus Characterization of delta , kappa , and µ Human Opioid Receptors Overexpressed in Baculovirus-infected Insect Cells J. Biol. Chem., August 8, 1997; 272(32): 19987 - 19992. [Abstract] [Full Text] [PDF]